Loading...
•
Dec 31, 2025
Cytokinetics Q4 2025 Earnings Report
Cytokinetics reported fourth quarter 2025 financial results and transitioned to a commercial-stage company following the FDA approval of MYQORZO.
Key Takeaways
Cytokinetics achieved a major milestone in Q4 2025 with the FDA approval of MYQORZO for obstructive hypertrophic cardiomyopathy. While the company reported a net loss of $183 million for the quarter, it ended the year with a strong cash position of $1.22 billion to support its U.S. commercial launch and ongoing Phase 3 clinical trials.
MYQORZO received regulatory approvals in the U.S., China, and Europe for the treatment of symptomatic obstructive HCM.
The U.S. commercial launch of MYQORZO is underway with the first prescriptions dispensed in early 2026.
Total Q4 revenue was $17.8 million, primarily driven by a $15 million milestone payment from Sanofi.
The company maintains a robust balance sheet with $1.22 billion in cash, equivalents, and investments as of year-end 2025.
Revenue by Segment
Forward Guidance
Cytokinetics provided 2026 financial guidance focusing on the commercial launch of MYQORZO and continued clinical development.
Positive Outlook
- Expected launch of MYQORZO in Germany in Q2 2026.
- Anticipated topline results from ACACIA-HCM in Q2 2026.
- Potential FDA approval of sNDA for MAPLE-HCM in Q4 2026.
- Potential approval from Health Canada in 2H 2026.
- Completion of enrollment in several key clinical cohorts (CEDAR-HCM, AMBER-HFpEF).
Challenges Ahead
- GAAP Combined R&D and SG&A expenses expected to be high, between $830 million and $870 million.
- Guidance does not include potential costs for commercializing aficamten in nHCM.
- Guidance excludes collaboration expenses and cost of inventory sales to partners.
- Ongoing heavy investment in U.S. and European commercial infrastructure.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...